PKMYT1 Inhibitor (EVT-3023)

About Evariste Technologies

Evariste Technologies is a private, preclinical-stage biotech applying advanced mathematical modeling and machine learning to discover and develop small molecule drugs for synthetic lethal oncology indications. Its core asset is the Frobenius AI platform, which integrates multi-omic data for novel target identification and employs machine learning for efficient small molecule design and optimization. The company has built an early pipeline featuring programs against targets like PKMYT1 and VRK1, and is led by a team with expertise in drug discovery, AI, and mathematics.

Therapeutic Areas